Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes

Article Medicine, General & Internal

Empagliflozin in Patients with Chronic Kidney Disease

William G. Herrington et al.

Summary: Empagliflozin therapy reduces the risk of disease progression or cardiovascular death in patients with chronic kidney disease.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Neurosciences

Association of Type 2 Diabetes Mellitus with Cognitive Function in Adults: A Prospective Cohort Study

Xiao Chen et al.

Summary: This study examined the association between type 2 diabetes mellitus (T2DM) and untreated T2DM with cognitive function among middle-aged and older Chinese adults. The findings showed that untreated T2DM was associated with worse cognitive function, particularly in executive function. Therefore, screening and early treatment for T2DM are necessary for maintaining better cognitive function in later life.

JOURNAL OF ALZHEIMERS DISEASE (2023)

Add to Collection

Editorial Material Transplantation

What should European nephrology do with the new CKD-EPI equation?

Ron T. Gansevoort et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Add to Collection

Article Medicine, General & Internal

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

S. E. E. Nissen et al.

Summary: This study demonstrates that the ATP citrate lyase inhibitor Bempedoic acid can significantly reduce low-density lipoprotein cholesterol levels and is associated with a low incidence of muscle-related adverse events. Among patients unable or unwilling to take statins, Bempedoic acid treatment significantly reduces the risk of major adverse cardiovascular events.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Endocrinology & Metabolism

Glycemic Targets: Standards of Care in Diabetes-2023

Nuha A. ElSayed et al.

DIABETES CARE (2023)

Add to Collection

Article Endocrinology & Metabolism

Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023

Nuha A. ElSayed et al.

DIABETES CARE (2023)

Add to Collection

Article Endocrinology & Metabolism

Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023

Nuha A. ElSayed et al.

DIABETES CARE (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Interaction between smoking and diabetes in relation to subsequent risk of cardiovascular events

Yang Yang et al.

Summary: Smoking and diabetes interact with each other in relation to increased risk of cardiovascular disease events, and the beneficial effect of risk factor management on cardiovascular disease risk among participants with diabetes is attenuated by smoking.

CARDIOVASCULAR DIABETOLOGY (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial

Carolyn S. P. Lam et al.

Summary: The analysis of the AMPLITUDE-O trial suggests that the efficacy and safety of Efpeglenatide are not impacted by concurrent use of SGLT2 inhibitors. These data support the combined use of SGLT2 inhibitors and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes.

CIRCULATION (2022)

Add to Collection

Article Endocrinology & Metabolism

8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes-2022

Summary: The American Diabetes Association's Standards of Medical Care in Diabetes provides clinical practice recommendations, treatment goals, and guidelines for diabetes care, as well as tools for evaluating care quality. The standards are updated annually or more frequently as needed by the ADA's Professional Practice Committee.

DIABETES CARE (2022)

Add to Collection

Review Endocrinology & Metabolism

Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials

Ajay Chaudhuri et al.

Summary: Diabetes and chronic kidney disease (CKD) are significant issues for adults worldwide, but traditional treatment approaches have limitations. Recent research suggests that novel disease-modifying agents targeting inflammatory and fibrotic factors may have beneficial effects on CKD progression and cardiovascular outcomes.

DIABETES OBESITY & METABOLISM (2022)

Add to Collection

Article Nutrition & Dietetics

Factors associated with successful dietary changes in an energy-reduced Mediterranean diet intervention: a longitudinal analysis in the PREDIMED-Plus trial

Cesar Fernandez-Lazaro et al.

Summary: The study indicated that participants with high baseline perceived self-efficacy, higher fiber intake, multiple chronic conditions (especially depression) were more likely to successfully comply with an energy-reduced Mediterranean diet. Tailored interventions focusing on these factors may lead to greater dietary changes and nutritional improvements.

EUROPEAN JOURNAL OF NUTRITION (2022)

Add to Collection

Review Endocrinology & Metabolism

Complications of Diabetes and Metrics of Glycemic Management Derived From Continuous Glucose Monitoring

Michael Yapanis et al.

Summary: This review summarizes the relationship between continuous glucose monitoring (CGM)-derived metrics of glycemic variability and diabetes-related complications. The results show that glycemic variability and low time in range (TIR) are associated with microvascular and macrovascular complications of diabetes. Higher TIR is associated with reduced risk of various complications, while standard deviation of blood glucose levels (SD) and mean amplitude of glycemic excursions (MAGE) are associated with peripheral neuropathy.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

Add to Collection

Review Endocrinology & Metabolism

Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations

Jose L. Gorriz et al.

Summary: GLP-1 RAs have benefits beyond reducing blood glucose in people with type 2 diabetes and chronic kidney disease, including improving kidney function and reducing cardiovascular events. However, their use is uncommon in this patient population, and it is important for physicians to understand their benefits and practical use to achieve positive patient outcomes.

DIABETES THERAPY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Adriaan A. Voors et al.

Summary: The sodium-glucose cotransporter 2 inhibitor empagliflozin improves clinical outcomes in patients hospitalized for acute heart failure, regardless of ejection fraction or the presence of diabetes.

NATURE MEDICINE (2022)

Add to Collection

Review Surgery

Effect of bariatric surgery on long-term cardiovascular outcomes: a systematic review and meta-analysis of population-based cohort studies

Borui Tang et al.

Summary: Bariatric surgery in obese patients has shown significant advantages in reducing cardiovascular events compared to nonsurgical treatment, especially in patients with comorbid diabetes. Long-term follow-up also demonstrates a more pronounced effect.

SURGERY FOR OBESITY AND RELATED DISEASES (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Targeted Strategy in Lipid-Lowering Therapy

Ezgi Dayar et al.

Summary: This article introduces the mechanisms and classifications of lipid-lowering drugs, as well as targeted therapy and alternative treatments to help reduce or prevent atherosclerosis and cardiovascular events.

BIOMEDICINES (2022)

Add to Collection

Article Chemistry, Medicinal

Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives

Rosanna Maccari et al.

Summary: SGLT-2 inhibitors, such as gliflozins, are a recently approved class of oral antidiabetic drugs that improve glycemic control through a novel insulin-independent mechanism of action and exhibit significant cardiorenal protective effects. The discovery of the potential of intestinal SGLT-1 inhibition has led to the design of low adsorbable inhibitors selectively targeting the intestinal SGLT-1 subtype, as well as dual SGLT-1/SGLT-2 inhibitors, which provide a compelling strategy for identifying new antidiabetic drug candidates.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection

Review Urology & Nephrology

Tirzepatide and prevention of chronic kidney disease

Catalina Bosch et al.

Summary: Tirzepatide is a recently approved dual hormone for improving glycemic control in type 2 diabetes mellitus. It has also shown potential in reducing body weight, improving cardiovascular risk factors, and protecting kidney health in individuals with diabetes.

CLINICAL KIDNEY JOURNAL (2022)

Add to Collection

Article Endocrinology & Metabolism

The Global Burden of Type 2 Diabetes Attributable to Tobacco: A Secondary Analysis From the Global Burden of Disease Study 2019

Jianjun Bai et al.

Summary: This study aimed to explore the global secular trend and spatial distribution of the burden of tobacco-attributable type 2 diabetes (T2D) on a global scale. The results showed that tobacco posed a challenge to global T2D health, particularly for the elderly and men from lower socio-demographic index regions. The study also found regional disparities, with hotspots mainly concentrated in South Africa and Southeast Asian countries.

FRONTIERS IN ENDOCRINOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes

Elisabeth Ng et al.

Australian Journal of General Practice (2022)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

S. D. Solomon et al.

Summary: The study shows that SGLT2 inhibitors are effective in reducing the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or less. However, whether they are effective in patients with a higher left ventricular ejection fraction remains uncertain.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Review Medicine, General & Internal

A review of cardiovascular benefits of SGLT2 inhibitors

Yingxia Zhang et al.

Summary: This article summarizes the multiple protective effects of Sodium-glucose cotransporter 2 inhibitor (SGLT2I) and its possible mechanisms in the treatment of heart diseases and hypertension.

MEDICINE (2022)

Add to Collection

Letter Cardiac & Cardiovascular Systems

Half of patients with type 2 diabetes mellitus are at very high cardiovascular risk according to the ESC/EASD: data from a large Mediterranean population

Ana M. Cebrian-Cuenca et al.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2022)

Add to Collection

Article Endocrinology & Metabolism

Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses fromDECLARE-TIMI58

Avivit Cahn et al.

Summary: The effects of dapagliflozin on cardiorenal outcomes were consistent regardless of baseline GLA, with significant benefits observed in patients using GLP-1 RAs. There was no interaction by baseline GLA for the reduction in renal-specific outcome seen with dapagliflozin in the overall cohort. Further exploration into the potential clinical benefit of combining sodium-glucose co-transporter-2 inhibitors with GLP-1 RAs is warranted.

DIABETES OBESITY & METABOLISM (2021)

Add to Collection

Article Endocrinology & Metabolism

Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes

Brendon L. Neuen et al.

Summary: The study assessed the effects of SGLT2 inhibitors on cardiovascular, kidney, and mortality outcomes, finding that regardless of concomitant metformin use, SGLT2 inhibitors reduced the risk of MACE and HHF or cardiovascular death. There were also effects on major kidney outcomes and all-cause mortality.

DIABETES OBESITY & METABOLISM (2021)

Add to Collection

Review Endocrinology & Metabolism

Diabetes remission after bariatric surgery

Maryna Chumakova-Orin et al.

Summary: Obesity rates have continued to rise, in parallel with increasing rates of type 2 diabetes mellitus. Bariatric surgery provides better T2DM resolution in obese patients, with Biliopancreatic diversion and Roux-en-Y gastric bypass showing higher rates of T2DM resolution compared to other procedures.

WORLD JOURNAL OF DIABETES (2021)

Add to Collection

Review Pharmacology & Pharmacy

Efficacy and Cardiovascular Safety of Sulfonylureas

Cornelius James Fernandez et al.

Summary: This review critically analyzes the efficacy and cardiovascular safety of sulfonylureas, shedding light on their potential role in the treatment of hyperglycemia.

CURRENT DRUG SAFETY (2021)

Add to Collection

Article Endocrinology & Metabolism

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)

Juan P. Frias et al.

Summary: The study compared the efficacy and safety of different doses of dulaglutide in patients with inadequately controlled type 2 diabetes, demonstrating that higher doses of dulaglutide were more effective in reducing HbA(1c) and body weight.

DIABETES CARE (2021)

Add to Collection

Review Endocrinology & Metabolism

SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review

Carlos Escobar et al.

Summary: Results from this study show that in type 2 diabetes patients not using metformin, GLP1-RAs and SGLT2 inhibitors significantly reduce the risk of MACE compared to placebo. This suggests that these two medications may help in reducing the risk of cardiovascular events.

DIABETIC MEDICINE (2021)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Cardiometabolic Center of Excellence: A Novel Care Delivery Model for Secondary Prevention of Cardiovascular Disease in Type 2 Diabetes

Merrill Thomas et al.

Summary: Additional digital content is available within the text.

CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2021)

Add to Collection

Article Peripheral Vascular Disease

Routine assessment of cognitive function in older patients with hypertension seen by primary care physicians: why and how-a decision-making support from the working group on 'hypertension and the brain' of the European Society of Hypertension and from the European Geriatric Medicine Society

Angelo Scuteri et al.

Summary: The European Societies of Hypertension and Cardiology guidelines have recognized cognitive function decline as a hypertension-mediated organ damage, which can be the only hypertension-mediated organ damage in over 30% of hypertensive patients. It is crucial for the medical community to have a pragmatic approach to identify and treat these patients early. Moreover, there is a clear connection between exposure to high blood pressure and the development of cognitive decline, making it necessary to standardize clinical evaluation and treatment practices for hypertensive patients, especially in older populations.

JOURNAL OF HYPERTENSION (2021)

Add to Collection

Article Medicine, General & Internal

Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial

Geltrude Mingrone et al.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

Deepak L. Bhatt et al.

Summary: The trial involving 10,584 patients with diabetes and chronic kidney disease showed that sotagliflozin resulted in fewer deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure compared to placebo. However, there were adverse events such as diarrhea, mycotic infections, and diabetic ketoacidosis associated with sotagliflozin.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Deepak L. Bhatt et al.

Summary: In patients with diabetes and recent worsening heart failure, treatment with sotagliflozin significantly reduced the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure compared to placebo, regardless of the timing of administration.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Endocrinology & Metabolism

What's in a Name? Redefining Type 2 Diabetes Remission

Sanjay Kalra et al.

Summary: Diabetes remission is a concept that lacks consensus, with this article proposing a definition focused on maintaining HBA1c levels below target for at least 6 months. This state of remission should not be attributed to complications, comorbid conditions, or concomitant therapy, reflecting a healthy clinical status.

DIABETES THERAPY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update

Husam M. Salah et al.

Summary: Nine randomized clinical trials involving 60,914 patients with type 2 diabetes showed that the use of SGLT2 and dual SGLT1/2 inhibitors can improve cardiovascular and kidney outcomes.

AMERICAN HEART JOURNAL (2021)

Add to Collection

Article Endocrinology & Metabolism

Sodium-glucose co-transporter-2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis

Dario Giugliano et al.

Summary: This meta-analysis evaluates the cardiorenal outcomes of SGLT-2is in patients with type 2 diabetes, finding that SGLT-2is are associated with a reduced risk of major adverse cardiovascular events and significant benefits in the progression of diabetic kidney disease. There was no significant heterogeneity observed based on the presence or absence of cardiovascular disease in patients.

DIABETES OBESITY & METABOLISM (2021)

Add to Collection

Article Medicine, General & Internal

Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, doubleblind, double-dummy, placebo-controlled, phase 3 trial

Melanie Davies et al.

Summary: In this study, once-weekly subcutaneous semaglutide 2.4 mg was shown to achieve a significantly greater and clinically meaningful weight reduction compared to placebo in adults with overweight or obesity and type 2 diabetes. Adverse events, particularly gastrointestinal events, were more common with semaglutide compared to placebo.

LANCET (2021)

Add to Collection

Review Endocrinology & Metabolism

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

Naveed Sattar et al.

Summary: The meta-analysis showed that GLP-1 receptor agonists can reduce the risk of major adverse cardiovascular events, all-cause mortality, hospital admission for heart failure, and worsening kidney function in patients with type 2 diabetes, regardless of structural homology.

LANCET DIABETES & ENDOCRINOLOGY (2021)

Add to Collection

Article Environmental Sciences

Insulin Withdrawal in Diabetic Kidney Disease: What Are We Waiting for?

Carlos Morillas et al.

Summary: The prevalence of type 2 diabetes mellitus is nearly 9.3%, with 20-40% of patients developing diabetic kidney disease (DKD). Overweight or obese patients often have insulin resistance, but GLP1-RA and SGLT2i have shown benefits for renal and cardiovascular targets in CKD patients. New guidelines recommend the use of these medications in the treatment of CKD patients.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2021)

Add to Collection

Review Endocrinology & Metabolism

GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials

Apostolos Tsapas et al.

Summary: The study found that GLP-1 receptor agonists have a beneficial effect on cardiovascular outcomes regardless of baseline metformin use, with neutral effects on the incidence of myocardial infarction, stroke, and heart failure.

DIABETES RESEARCH AND CLINICAL PRACTICE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC)

Frank L. J. Visseren et al.

EUROPEAN HEART JOURNAL (2021)

Add to Collection

Article Medicine, General & Internal

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

Bertram Pitt et al.

Summary: Finerenone therapy improved cardiovascular outcomes in patients with type 2 diabetes and stage 2 to 4 CKD with moderately elevated albuminuria or stage 1 or 2 CKD with severely elevated albuminuria, compared to placebo. The risk of the primary outcome event was significantly lower in the finerenone group, primarily driven by a reduction in hospitalization for heart failure.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker et al.

Summary: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes

Hertzel C. Gerstein et al.

Summary: The trial compared the cardiovascular and renal outcomes of weekly injections of efpeglenatide versus a placebo in participants with type 2 diabetes and a history of cardiovascular disease or current kidney disease. The study found that the risk of cardiovascular events was lower with efpeglenatide treatment, and a composite renal outcome event was also reduced.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Endocrinology & Metabolism

Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial

Juan P. Frias et al.

Summary: The study compared the efficacy and safety of once-weekly semaglutide 2.0 mg and 1.0 mg in adults with inadequately controlled type 2 diabetes. The results showed that semaglutide 2.0 mg was superior in reducing HbA1c, with additional bodyweight loss and a similar safety profile, providing a treatment intensification option for patients in need of additional glycaemic control.

LANCET DIABETES & ENDOCRINOLOGY (2021)

Add to Collection

Review Endocrinology & Metabolism

Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer anti-hyperglycaemic drug matters?

Dario Giugliano et al.

DIABETES OBESITY & METABOLISM (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

Francesco Cosentino et al.

EUROPEAN HEART JOURNAL (2020)

Add to Collection

Article Cell Biology

Hepatic Lipoprotein Export and Remission of Human Type 2 Diabetes after Weight Loss

Ahmad Al-Mrabeh et al.

CELL METABOLISM (2020)

Add to Collection

Review Chemistry, Medicinal

Mechanisms and Characteristics of Sulfonylureas and Glinides

Wei Lv et al.

CURRENT TOPICS IN MEDICINAL CHEMISTRY (2020)

Add to Collection

Article Endocrinology & Metabolism

2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

John B. Buse et al.

DIABETOLOGIA (2020)

Add to Collection

Article Endocrinology & Metabolism

Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial

Athena Philis-Tsimikas et al.

DIABETOLOGIA (2020)

Add to Collection

Article Endocrinology & Metabolism

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM-2020 EXECUTIVE SUMMARY

Alan J. Garber et al.

ENDOCRINE PRACTICE (2020)

Add to Collection

Article Endocrinology & Metabolism

Semaglutide once weekly in people with type 2 diabetes: Real-world analysis of the CanadianLMCdiabetes registry (SPAREstudy)

Ruth E. Brown et al.

DIABETES OBESITY & METABOLISM (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis

Xing Wang et al.

CARDIOVASCULAR DIABETOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study

Juan J. Gorgojo-Martinez et al.

JOURNAL OF CLINICAL MEDICINE (2020)

Add to Collection

Review Pharmacology & Pharmacy

Renal protection with glucagon-like peptide-1 receptor agonists

Martina Vitale et al.

CURRENT OPINION IN PHARMACOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis

Xiaoyan Cai et al.

BMJ-British Medical Journal (2020)

Add to Collection

Review Endocrinology & Metabolism

Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus

Carolyn F. Deacon

NATURE REVIEWS ENDOCRINOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Milton Packer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin in Patients with Chronic Kidney Disease

Hiddo J. L. Heerspink et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

George L. Bakris et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

Christopher P. Cannon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Endocrinology & Metabolism

GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art

Michael A. Nauck et al.

MOLECULAR METABOLISM (2020)

Add to Collection

Article Urology & Nephrology

Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2 Subgroup Analysis of the Randomized CREDENCE Trial

George Bakris et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)

Add to Collection

Article Urology & Nephrology

Bloqueantes del receptor mineralcorticoide en la enfermedad renal crónica

Sara Erraez et al.

NEFROLOGIA (2020)

Add to Collection

Review Substance Abuse

Risk of Coronary Heart Disease Among Smokeless Tobacco Users: Results of Systematic Review and Meta-Analysis of Global Data

Ruchika Gupta et al.

NICOTINE & TOBACCO RESEARCH (2019)

Add to Collection

Review Medicine, General & Internal

What is new in lipid-lowering therapies in diabetes?

Yee-Ming Cheung et al.

INTERNAL MEDICINE JOURNAL (2019)

Add to Collection

Article Medicine, General & Internal

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

V. Perkovic et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Endocrinology & Metabolism

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range

Tadej Battelino et al.

DIABETES CARE (2019)

Add to Collection

Article Medicine, General & Internal

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein et al.

LANCET (2019)

Add to Collection

Article Medicine, General & Internal

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Mansoor Husain et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial

Julio Rosenstock et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

J. J. V. McMurray et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Pharmacology & Pharmacy

Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes

Maka S. Hedrington et al.

EXPERT OPINION ON PHARMACOTHERAPY (2019)

Add to Collection

Article Medicine, General & Internal

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial

Julio Rosenstock et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

S. D. Wiviott et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

Deepak L. Bhatt et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Multidisciplinary Sciences

Long-term outcomes of macrovascular diseases and metabolic indicators of bariatric surgery for severe obesity type 2 diabetes patients with a meta-analysis

Guoli Yan et al.

PLOS ONE (2019)

Add to Collection

Article Endocrinology & Metabolism

The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States

Wayne Weng et al.

ENDOCRINOLOGY DIABETES & METABOLISM (2019)

Add to Collection

Review Biochemistry & Molecular Biology

Thiazolidinediones as antidiabetic agents: A critical review

M. J. Nanjan et al.

BIOORGANIC CHEMISTRY (2018)

Add to Collection

Article Endocrinology & Metabolism

Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience

Bernard Zinman et al.

DIABETES CARE (2018)

Add to Collection

Article Endocrinology & Metabolism

Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial

Helena W. Rodbard et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)

Add to Collection

Article Medicine, General & Internal

Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial

Michael E. J. Lean et al.

LANCET (2018)

Add to Collection

Article Endocrinology & Metabolism

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial

Katherine R. Tuttle et al.

LANCET DIABETES & ENDOCRINOLOGY (2018)

Add to Collection

Article Endocrinology & Metabolism

Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial

Serge A. Jabbour et al.

DIABETES CARE (2018)

Add to Collection

Review Cardiac & Cardiovascular Systems

2018 ESC/ESH Guidelines for the management of arterial hypertension

Bryan Williams et al.

EUROPEAN HEART JOURNAL (2018)

Add to Collection

Article Medicine, General & Internal

Smoking Cessation, Weight Change, Type 2 Diabetes, and Mortality

Yang Hu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez et al.

LANCET (2018)

Add to Collection

Article Endocrinology & Metabolism

DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality

Thomas R. Pieber et al.

DIABETOLOGIA (2018)

Add to Collection

Article Endocrinology & Metabolism

Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)

Bernard Zinman et al.

DIABETOLOGIA (2018)

Add to Collection

Article Endocrinology & Metabolism

The Association of Severe Hypoglycemia With Incident Cardiovascular Events and Mortality in Adults With Type 2 Diabetes

Alexandra K. Lee et al.

DIABETES CARE (2018)

Add to Collection

Review Peripheral Vascular Disease

Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10-Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials

Costas Thomopoulos et al.

JOURNAL OF HYPERTENSION (2017)

Add to Collection

Article Medicine, General & Internal

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

Steven P. Marso et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

Rury R. Holman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Review Surgery

The Long-Term Effects of Bariatric Surgery on Type 2 Diabetes Remission, Microvascular and Macrovascular Complications, and Mortality: a Systematic Review and Meta-Analysis

Binwu Sheng et al.

OBESITY SURGERY (2017)

Add to Collection

Article Cardiac & Cardiovascular Systems

Efficacy and Safety of Smoking Cessation Interventions in Patients With Cardiovascular Disease: A Network Meta-Analysis of Randomized Controlled Trials

Karine Suissa et al.

CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2017)

Add to Collection

Article Cardiac & Cardiovascular Systems

Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry®

Suzanne V. Arnold et al.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)

Add to Collection

Article Endocrinology & Metabolism

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA. IT): a randomised, multicentre trial

Olga Vaccaro et al.

LANCET DIABETES & ENDOCRINOLOGY (2017)

Add to Collection

Article Endocrinology & Metabolism

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial

Rury R. Holman et al.

LANCET DIABETES & ENDOCRINOLOGY (2017)

Add to Collection

Review Endocrinology & Metabolism

Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes

Simon J. Griffin et al.

DIABETOLOGIA (2017)

Add to Collection

Review Endocrinology & Metabolism

The impact of smoking on the development of diabetes and its complications

Mariola Sliwinska-Mosson et al.

DIABETES & VASCULAR DISEASE RESEARCH (2017)

Add to Collection

Review Endocrinology & Metabolism

Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies

Laurent Azoulay et al.

DIABETES CARE (2017)

Add to Collection

Article Endocrinology & Metabolism

Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial

Thomas Idorn et al.

DIABETES CARE (2016)

Add to Collection

Article Endocrinology & Metabolism

Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations

Francesco Rubino et al.

DIABETES CARE (2016)

Add to Collection

Article Endocrinology & Metabolism

Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial

Peter Gde et al.

DIABETOLOGIA (2016)

Add to Collection

Article Endocrinology & Metabolism

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY

W. Timothy Garvey et al.

ENDOCRINE PRACTICE (2016)

Add to Collection

Article Medicine, General & Internal

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

W. N. Kernan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Medicine, General & Internal

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Christoph Wanner et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Medicine, General & Internal

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Steven P. Marso et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Medicine, General & Internal

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Steven P. Marso et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Endocrinology & Metabolism

Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial

Edward W. Gregg et al.

LANCET DIABETES & ENDOCRINOLOGY (2016)

Add to Collection

Article Medicine, General & Internal

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Jennifer B. Green et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Review Endocrinology & Metabolism

Effect of orlistat on glycaemic control in overweight and obese patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

N. M. Aldekhail et al.

OBESITY REVIEWS (2015)

Add to Collection

Article Endocrinology & Metabolism

Update on Cardiovascular Outcomes at 30 Years of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study

John M. Lachin et al.

DIABETES CARE (2014)

Add to Collection

Article Endocrinology & Metabolism

Severe Hypoglycemia-Induced Lethal Cardiac Arrhythmias Are Mediated by Sympathoadrenal Activation

Candace M. Reno et al.

DIABETES (2013)

Add to Collection

Article Medicine, General & Internal

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

William B. White et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Article Medicine, General & Internal

被撤回的出版物: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet (Retracted article. See vol. 378, pg. 2441, 2018)

Ramon Estruch et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Article Medicine, General & Internal

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

Benjamin M. Scirica et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Article Medicine, General & Internal

Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis

Atsushi Goto et al.

BMJ-BRITISH MEDICAL JOURNAL (2013)

Add to Collection

Article Pharmacology & Pharmacy

Rosiglitazone, Myocardial Ischemic Risk, and Recent Regulatory Actions

Catherine A. Bourg et al.

ANNALS OF PHARMACOTHERAPY (2012)

Add to Collection

Review Medicine, General & Internal

Physical Activity and Mortality in Individuals With Diabetes Mellitus A Prospective Study and Meta-analysis

Diewertje Sluik et al.

ARCHIVES OF INTERNAL MEDICINE (2012)

Add to Collection

Article Endocrinology & Metabolism

Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study

F. Soriguer et al.

DIABETOLOGIA (2012)

Add to Collection

Article Medicine, General & Internal

Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia

Hertzel C. Gerstein et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Review Cardiac & Cardiovascular Systems

Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR (Part II)

L. Vanhees et al.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2012)

Add to Collection

Article Medicine, General & Internal

Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials

Bianca Hemmingsen et al.

BMJ-BRITISH MEDICAL JOURNAL (2011)

Add to Collection

Article Medicine, General & Internal

Effects of Aerobic and Resistance Training on Hemoglobin A1c Levels in Patients With Type 2 Diabetes A Randomized Controlled Trial

Timothy S. Church et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)

Add to Collection

Article Medicine, General & Internal

Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events

Rury R. Holman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Add to Collection

Article Medicine, General & Internal

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

Denise E. Bonds et al.

BMJ-BRITISH MEDICAL JOURNAL (2010)

Add to Collection

Article Pharmacology & Pharmacy

Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide

Lisbeth V. Jacobsen et al.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)

Add to Collection

Article Medicine, General & Internal

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

Kausik K. Ray et al.

LANCET (2009)

Add to Collection

Article Medicine, General & Internal

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

Anushka Patel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Add to Collection

Article Medicine, General & Internal

Effect of a multifactorial intervention on mortality in type 2 diabetes

Peter Gaede et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Add to Collection

Article Endocrinology & Metabolism

Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents

Stephen N. Davis et al.

DIABETES CARE (2007)

Add to Collection

Article Medicine, General & Internal

Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes

DM Nathan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

Add to Collection

Article Medicine, General & Internal

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial

JA Dormandy et al.

LANCET (2005)

Add to Collection

Article Medicine, General & Internal

Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial

JL Chiasson et al.

LANCET (2002)

Add to Collection

Article Medicine, General & Internal

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

BM Brenner et al.

NEW ENGLAND JOURNAL OF MEDICINE (2001)

Add to Collection

Article Medicine, General & Internal

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

EJ Lewis et al.

NEW ENGLAND JOURNAL OF MEDICINE (2001)

Add to Collection

Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes

Related references

Export Citation

Share Paper